Inspire Revenue
Pharmaceutical Manufacturing • 
United States • 201-500 Employees
Inspire revenue & valuation
| Annual revenue | $300,000,000 |
| Revenue per employee | $682,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $960,000,000 |
| Total funding | No funding |
Key Contacts at Inspire
David Blagbrough
Director
Mohammad Afsar
Ceo
Sharmin Rahman
Founder
Kim Davis
Director, Regulatory Affairs
Michael Schiewe
Associate Director Clinical Research Ophthalmology
Nigel Edghill
Owner
Mahmoud Sedik
Art Director
Angelique Nkunzimana
Staff Nurse/ Director
Rick Powers
Regional Sales Director
Amada Elena Alvarerez Blanquicet
Director De Marketing En Línea
Company overview
| Headquarters | United States |
| Websites | |
| NAICS | 3254 |
| Founded | 1995 |
| Employees | 201-500 |
| Socials |
Inspire Email Formats
Inspire uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 54.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name}@company.com | john.doe@company.com | 54.7% |
{first name initial}{last name}@company.com | {first name initial}doe@company.com | 19.2% |
{last name}.{first name}@company.com | doe.john@company.com | 11.3% |
{first name}@company.com | john@company.com | 9.1% |
{first name}{last name}@company.com | johndoe@company.com | 5.7% |
About Inspire
Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire's goal is to build and commercialize a sustainable portfolio of innovative new products based on its technical, scientific and commercial expertise. The most advanced compounds in Inspire's clinical pipeline are denufosol tetrasodium for cystic fibrosis and PROLACRIA(TM) (diquafosol tetrasodium ophthalmic solution) 2% for dry eye, which are both in Phase 3 development, and AZASITE(R) (azithromycin ophthalmic solution) 1% for blepharitis, which is in Phase 2 development. Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye.
Employees by Management Level
Total employees: 201-500
Seniority
Employees
Employees by Department
Inspire has 97 employees across 15 departments.
Departments
Number of employees
Funding Data
Inspire has never raised funding before.
Canada
Frequently asked questions
4.8
40,000 users
